Phenotypic characterization of tumor CTLA-4 expression in melanoma tissues and its possible role in clinical response to Ipilimumab

Maria Pia Pistillo, Roberta Carosio, Federica Grillo, Vincenzo Fontana, Luca Mastracci, Anna Morabito, Barbara Banelli, Enrica Tanda, Federica Cecchi, Beatrice Dozin, Marina Gualco, Sandra Salvi, Francesco Spagnolo, Alessandro Poggi, Paola Queirolo

Research output: Contribution to journalArticle


The expression of the immune checkpoint molecule CTLA-4 has been almost exclusively studied in the T cell lineage, but increasing evidence has shown its expression on tumors with implications for immunotherapy. To date, the degree of expression of CTLA-4 on tumor cells as a predictive biomarker of response to immune checkpoint inhibitors has not been studied. In this report, we analyzed this issue in melanoma patients treated with CTLA-4 inhibitor Ipilimumab (IPI). We show that the level of CTLA-4 expression on melanoma cells is higher than that on tumor infiltrating lymphocytes (TIL) and it is associated with clinical response to IPI therapy supporting the idea of its possible role as a predictive biomarker.

Original languageEnglish
Article number108428
JournalClinical Immunology
Publication statusPublished - Jun 2020



  • Best overall response
  • CTLA-4
  • Immunohistochemistry
  • Ipilimumab
  • Melanoma
  • TIL

ASJC Scopus subject areas

  • Immunology and Allergy
  • Immunology

Cite this